Isofol Medical Overview
- Founded
-
2008
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
ISOFOL
- Investments
-
1
- Share Price
-
$0.78
- (As of Thursday Closing)
Isofol Medical General Information
Description
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Hospitals/Inpatient Services
Stock Exchange
STO
Primary Office
- Biotech Center
- Arvid Wallgrens Backe 20
- 413 46 Gothenburg
- Sweden
+46 031-797 00 00
Isofol Medical Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.78 | $0.85 | $0.73 - $1.60 | $126M | 162M | 178K | -$0.17 |
Isofol Medical Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 121,714 | 125,604 | 267,661 | 50,093 |
| Revenue | 2,402 | 2,609 | 4,026 | 0 |
| EBITDA | (23,116) | (23,113) | (20,289) | (16,901) |
| Net Income | (23,281) | (23,318) | (20,497) | (17,084) |
| Total Assets | 37,824 | 44,350 | 18,058 | 15,666 |
| Total Debt | 36 | 183 | 380 | 448 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Isofol Medical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Isofol Medical Patents
Isofol Medical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190212341-A1 | Methods for treating colorectal and metastatic colorectal cancers | Pending | 03-Apr-2018 | 0000000000 | |
| AU-2019205861-A1 | Methods for treating colorectal and metastatic colorectal cancers | Pending | 05-Jan-2018 | 00000000000 | |
| CA-3087514-A1 | Methods for treating colorectal and metastatic colorectal cancers | Pending | 05-Jan-2018 | 00000000000 | |
| JP-2021510140-A | How to treat colorectal cancer and metastatic colorectal cancer | Pending | 05-Jan-2018 | 00000000000 | |
| EP-3735267-A1 | Methods for treating colorectal and metastatic colorectal cancers | Pending | 05-Jan-2018 | A61K31/4745 |
Isofol Medical Executive Team (10)
Isofol Medical Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000 00.0 | Self | Board Member | 000 0000 |
| 0000 00000000000 00.0 | Self | Board Member | 000 0000 |
| 00000 00000000 | Isofol Medical | Board Member | 000 0000 |
Isofol Medical Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Isofol Medical Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 01-Jan-2010 | 00000 0000 | Drug Discovery |